Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab
Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1 New efficacy data from Roche’s portfolio of cancer immunotherapies demonstrate potential of bispecific antibodies to expand upon current treatment options across several blood cancers Basel,... Read more